EE250 An update of systematic review of cost-utility studies conducted from an Indian perspective

Abstract

Objectives: Cost-utility analysis (CUA) is the most preferred form of economic evaluation by HTA agencies such as NICE and PBAC. There is increasing interest in HTA in countries such as India. We previously conducted an SLR to identify CUA publications between November 2009 to November 2019. This is an update to our previous SLR to identify articles published between December 2019 to June 2022. Methods: Using Cochrane methodology, we updated our systematic review by running search on several databases such as PubMed, Cochrane and National Health Services Economic Evaluation Database (NHSEED). Only cost-utility studies published in English language were included. Conference and grey literature searches were also conducted using Google Scholar platform to identify relevant studies that were not captured by the database searches. Results: Similar number of studies (n=35) were identified in this update compared to the original SLR, although in a much smaller timeframe. Among the studies identified in this update, modelling method used were Markov (n=16), decision tree (n=7), a combination of decision tree and Markov (n=6), economic evaluation alongside clinical trial (n=3), modelling method not reported (n=2) and microsimulation model (n=1). The primary therapeutic areas targeted in CUA were infectious diseases (n = 10), oncology (n = 9), endocrine disorders (n = 5) and others disease (n = 11). While some studies covered multiple countries, others included multiple Indian states or didn`t report the region. Most of the studies utilised a 3% discount rate with range varying from 0% to 5%. The time horizon utilised varied from 6 days to lifetime. Conclusions: Maximum studies used Markov modelling method for the analyses and the lead therapeutic area were infectious disease and oncology. The increased number of published CUAs reflect the growing interest for economic evaluation in India.